Royalty Pharma acquired Biohaven Pharmaceuticals Holding Company for $150m.

Biohaven Pharmaceutical Holding Company Ltd. and Royalty Pharma announced today that Biohaven has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds thereof to Royalty Pharma for $100 million. Royalty Pharma has also agreed to purchase $50.0 million in common shares of Biohaven, at a price of $45.00 per share. These transactions are expected to provide sufficient cash to fund operations through the end of 2019.